antihypertensive action
Recently Published Documents


TOTAL DOCUMENTS

214
(FIVE YEARS 1)

H-INDEX

27
(FIVE YEARS 0)

2017 ◽  
Vol 14 (4) ◽  
pp. 27-31
Author(s):  
G A Baryshnikova ◽  
S A Chorbinskajya

The article deals with the choice of diuretic in arterial hypertension and presents data on the antihypertensive efficacy of the loop diuretic torasemide. Data on the mechanisms of antihypertensive action of torasemide are presented, including a unique antialdosterone effect. The article reports on the absence of a negative effect of the drug on carbohydrate, lipid, purine metabolism and electrolyte balance, positive effect on the target organs, very good tolerability. It is advisable to use torasemide more widely in a "non-diuretic" dose (2.5-5 mg / day) for the treatment of arterial hypertension as in monotherapy as in combination with other antihypertensive drugs.


2016 ◽  
Vol 34 (8) ◽  
pp. 1621-1629 ◽  
Author(s):  
Henrik Andersen ◽  
Pernille B.L. Hansen ◽  
Claus Bistrup ◽  
Flemming Nielsen ◽  
Jan Erik Henriksen ◽  
...  

2014 ◽  
Vol 2014 ◽  
pp. 1-6 ◽  
Author(s):  
Mei-Fen Chen ◽  
Jo-Ting Tsai ◽  
Li-Jen Chen ◽  
Tung-Pi Wu ◽  
Jia-Jang Yang ◽  
...  

The agonists of imidazoline I-1 receptors (I-1R) are widely used to lower blood pressure. It has been indicated that guanidinium derivatives show an ability to activate imidazoline receptors. Also, allantoin has a chemical stricture similar to guanidinium derivatives. Thus, it is of special interest to characterize the effect of allantoin on I-1R. In conscious male spontaneous hypertensive rats (SHRs), mean blood pressure (MBP) was recorded using the tail-cuff method. Furthermore, the hemodynamic analyses in catheterized rats were applied to measure the actions of allantoin in vivo. Allantoin decreased blood pressures in SHRs at 30 minutes, as the most effective time. Also, this antihypertensive action was shown in a dose-dependent manner from SHRs treated with allantoin. Moreover, in anesthetized rats, allantoin inhibited cardiac contractility and heart rate as showing in hemodynamicdP/dtmax significantly. Also, the peripheral blood flow was markedly increased by allantoin. Both actions were diminished by efaroxan at the dose sufficient to block I-1R. Thus, we suggest that allantoin, as I-1R agonist, has the potential to develop as a new therapeutic agent for hypertension in the future.


Sign in / Sign up

Export Citation Format

Share Document